Katherine C Dodd, Rohan Ahmed, Philip Ambrose, James Kl Holt, Saiju Jacob, M Isabel Leite, James Al Miller, Pyae Phyo San, Jennifer Spillane, Stuart Viegas, Jon Sussman
Azathioprine is recommended as the first-line steroid-sparing immunosuppressive agent for myasthenia gravis. Mycophenolate and methotrexate are often considered as second-line choices despite widespread consensus on their efficacy. We aimed to gather real-world data comparing the tolerability and reasons for discontinuation for these agents, by performing a national United Kingdom survey of side effects and reasons for discontinuation of immunosuppressants in myasthenia gravis. Of 235 patients, 166 had taken azathioprine, 102 mycophenolate, and 40 methotrexate...
March 21, 2024: Neuromuscular Disorders: NMD